Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by HighTower Advisors LLC

HighTower Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 27.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,648 shares of the specialty pharmaceutical company's stock after buying an additional 2,054 shares during the quarter. HighTower Advisors LLC's holdings in Jazz Pharmaceuticals were worth $1,188,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in JAZZ. Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares during the period. Franklin Resources Inc. grew its stake in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock valued at $124,208,000 after buying an additional 48,708 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 15.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock valued at $75,801,000 after buying an additional 83,807 shares during the period. Bank of New York Mellon Corp lifted its position in Jazz Pharmaceuticals by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after acquiring an additional 24,481 shares in the last quarter. Finally, GW&K Investment Management LLC boosted its holdings in Jazz Pharmaceuticals by 26.6% in the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock worth $57,142,000 after acquiring an additional 97,589 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $3.48 during trading on Friday, hitting $122.92. 1,709,286 shares of the company's stock traded hands, compared to its average volume of 735,368. The stock has a market capitalization of $7.47 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The stock has a fifty day moving average price of $132.30 and a two-hundred day moving average price of $122.54. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares of the company's stock, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,736 shares of company stock worth $4,022,825 over the last ninety days. Company insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on JAZZ shares. Barclays reissued an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Truist Financial lifted their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a report on Wednesday, February 26th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.